Immune-Mediated Inflammatory Disease and Obesity Bootcamp: A Comprehensive Overview
The 2025 SDPA Fall Conference witnessed a groundbreaking presentation by Laura Bush, DMSc, PA-C, on the Immune-Mediated Inflammatory Disease (IMID) and Obesity Bootcamp. This session, held in San Antonio, Texas, on November 5, aimed to educate advanced practice providers (APPs) about the intricate relationship between IMIDs and obesity, offering practical insights for improved patient care.
Laura Bush emphasized the significance of understanding obesity as an abnormal accumulation of adipose tissue, which exacerbates comorbid conditions. She shared a personal anecdote about a family member's experience with weight loss struggles, highlighting the emotional impact of obesity stigma. Bush advocated for using non-stigmatizing language and encouraged patients to overcome the fear of judgment.
The presentation delved into the link between inflammation, psoriasis, and obesity. Bush revealed a 66% increase in the odds of obesity among psoriasis patients, attributing it to limited social interactions and the fear of psoriasis-related stigma. This fear often leads to a sedentary lifestyle, creating a vicious cycle of inflammatory disease.
Furthermore, Bush discussed the epidemiological connection between inflammatory bowel disease (IBD) and psoriatic arthritis (PsA) with obesity. Research presented during the session indicated that a higher body mass index (BMI) at age 18 increases the risk of Crohn's disease. Obesity also diminishes the effectiveness of treatments for inflammatory conditions, necessitating higher medication doses.
Erin Darguzas, NP, contributed to the session by explaining the larger adipocyte size in obesity and the resulting storage of excess calories in adipose tissue. This leads to cell hypertrophy, triggering a cascade of responses in white adipose tissue, contributing to chronic, low-grade inflammation.
Amanda Mixon, PA-C, and Jennifer Hernandez-Parra, APRN, further emphasized the chronic nature of obesity, comparing it to other illnesses like diabetes. Mixon stressed the importance of a non-blaming, multidisciplinary approach, encouraging open conversations about obesity. She suggested weight loss drugs, the Mediterranean diet, and a calorie deficit as potential solutions.
Hernandez-Parra discussed the prevalence of obesity-related medications, such as GLP-1, and their prescription criteria, including BMI greater than 30. She highlighted comorbidities like previous heart attacks, moderate-to-severe obstructive sleep apnea, and type 2 diabetes as key considerations for medication eligibility.
This comprehensive bootcamp session provided valuable insights into the complex relationship between IMIDs and obesity, emphasizing the need for a holistic approach to patient care and management.
